Biomarker Quantitation: Analytical Considerations for Ligand Binding Assay Regression Curves and Quality Control Samples
DOI : 10.3844/ajisp.2012.71.77
American Journal of Immunology
Volume 8, 2012
As biomarkers grow in relevance for both the design and support of therapeutics and the clinical trials associated with them, there is an ever increasing need for accurate quantitation of these biochemical entities in biological matrices. While quantifying many biotherapeutics via ligand binding assay platforms can be fairly straightforward, biomarkers present some unique challenges that must be taken into account during assay development, validation and subsequent sample analysis. These challenges can be especially confounded by the relationship between two ligand binding assay tools: The regression curve and quality control samples. Due diligence must be performed to develop an assay that takes into account matrix vs. buffer effects and endogenous biomarker presence. Lack of diligence in these areas can lead to less than reliable results, thus potentially rendering the intended use of the assay moot.
© 2012 Mark Dysinger. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.